Spyre Therapeutics Stock Price, News & Analysis

Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at ACR Convergence 2025 on Oct 24, 2025 covering interim Phase 1 and preclinical data for SPY072.

Key points: six‑month follow‑up from the Phase 1 study shows SPY072 was reported as well tolerated, demonstrated a differentiated pharmacokinetic profile supporting quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 20 weeks at the lowest dose. Preclinical rodent data were presented showing anti‑TL1A treatment met or exceeded etanercept efficacy in a collagen‑induced arthritis model. Posters relate to the ongoing SKYWAY Phase 2 basket study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Posters are available via the ACR program.

Spyre Therapeutics (Nasdaq: SYRE) announced the closing of an underwritten public offering on Oct 15, 2025 of 17,094,594 shares of common stock, including the full exercise of a 2,229,729‑share underwriter option, at $18.50 per share. The offering generated approximately $316.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. A Form S‑3 registration (File No. 333‑285341) became effective on Mar 7, 2025. Joint book‑running managers included Jefferies, TD Securities, Leerink Partners and Stifel; Wedbush acted as lead manager.

Spyre Therapeutics (NASDAQ: SYRE) priced an underwritten public offering of 14,864,865 common shares at $18.50 per share, expected to generate approximately $275.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2,229,729 shares at the public offering price.

The offering is expected to close on or about October 15, 2025, subject to customary closing conditions. A registration statement (Form S-3, File No. 333-285341) became effective on March 7, 2025.

Spyre Therapeutics (Nasdaq: SYRE) announced on Oct 13, 2025 that it has commenced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities in the offering will be sold by Spyre. The company expects to grant underwriters a 30-day option to buy additional shares at the public offering price, less underwriting discount. The offering is subject to market and other conditions, and the final terms will be disclosed in a prospectus supplement filed with the SEC (Form S-3 File No. 333-285341).

Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at United European Gastroenterology Week (UEGW) 2025, according to the PR dated Oct 5, 2025.

The PR states interim Phase 1 data for SPY002 show it was well tolerated through six months, has a differentiated PK profile that the company says could support quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 24 weeks. The company also reported preclinical combination data where α4β7 + TL1A, α4β7 + IL‑23, and TL1A + IL‑23 combinations outperformed monotherapies in rodent TNBS colitis models. Posters and session details are available via the UEGW program, per the PR.

Spyre Therapeutics (NASDAQ: SYRE) announced on Oct 3, 2025 that its independent Compensation Committee approved inducement stock option awards to three non-executive employees under the 2018 Equity Inducement Plan.

The awards, approved on Oct 1, 2025, total 42,500 options with a 10-year term and an exercise price of $16.46—the Nasdaq closing price on Oct 1, 2025. Options vest 25% on the first anniversary of each employee’s start date and then monthly at 1/48th thereafter, subject to continued service, and remain subject to the terms of the 2018 Plan.

Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in its Phase 2 SKYWAY basket trial for SPY072, their pioneering anti-TL1A antibody targeting rheumatic diseases. The trial focuses on treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).

SPY072 is designed for superior potency and convenience, with potential for quarterly or twice-yearly subcutaneous maintenance dosing. The SKYWAY trial, alongside the SKYLINE study, is expected to provide 9 proof-of-concept readouts in 2026-27. The company targets commercial markets exceeding $60B in annual revenue, with topline data expected in 2026.

Spyre Therapeutics announced positive interim Phase 1 results for its anti-TL1A antibody programs SPY002 and SPY072, demonstrating favorable safety profiles and extended half-life supporting quarterly dosing. Both antibodies showed ~75-day half-life, over 3x longer than first-generation alternatives, with complete TL1A suppression through 20 weeks. The company initiated SKYLINE-UC platform trial in May 2025 for ulcerative colitis and announced SKYWAY-RD basket trial for rheumatologic conditions starting Q3 2025. With $60B+ market potential and cash runway into 2028, Spyre expects 9 Phase 2 readouts over next two years, including monotherapy and combination therapy data from SKYLINE-UC in 2026-2027, and results from SKYWAY-RD trial testing SPY072 in RA, PsA, and axSpA in 2026.

Spyre Therapeutics (NASDAQ: SYRE) has scheduled a conference call and webcast for June 17, 2025, at 8:00am ET to discuss interim results from Phase 1 healthy volunteer trials of their SPY002 program. The program focuses on novel half-life extended anti-TL1A antibodies for treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases. The presentation will be accessible through the company's Investor Relations webpage, with an archived version available for a limited time at https://ir.spyre.com/events-and-presentations.